Generic Name and Formulations:
Rimexolone 1%; oph susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for VEXOL:
Post-op inflammation. Anterior uveitis.
Post-op: 1–2 drops into conjunctival sac(s) 4 times daily; start 24 hrs after surgery and continue through 1st 2 weeks post-op. Uveitis: 1–2 drops into the conjunctival sac(s) every hour while awake for 1st week, then 1 drop every 2 hrs while awake for 2nd week, then taper until resolved.
Epithelial herpes simplex keratitis and other viral infections including vaccinia, varicella. Ocular mycobacterial, fungal, or untreated purulent infections.
Corneal or scleral thinning. Monitor intraocular pressure. Pregnancy (Cat.C). Nursing mothers: not recommended.
Blurred vision, discharge, discomfort, ocular pain, increased intraocular pressure, foreign body sensation, hyperemia, pruritus; may mask secondary ocular infections; ocular hypertension/glaucoma, optic nerve damage, defects in visual acuity and visual fields, posterior subcapsular cataract formation, superinfection possible with prolonged use.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib
- Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC
- Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC